Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28428266 | 0.83 | MIF (0.31) | MIFLMNA | |
| SCHEMBL13040003 | 0.81 | TSHR (0.41) | MIF | |
| SCHEMBL4002605 | 0.79 | LMNA (0.43) | MIFLMNA | |
| SCHEMBL16433410 | 0.78 | — | — | |
| SCHEMBL5570778 | 0.78 | — | — | |
| SCHEMBL11621178 | 0.77 | TSHR (0.39) | LMNA | |
| SCHEMBL9183340 | 0.76 | MIF (0.32) | MIFLMNA | |
| SCHEMBL4739892 | 0.76 | MIF (0.32) | MIFLMNA | |
| SCHEMBL9183404 | 0.76 | MIF (0.32) | MIFLMNA | |
| SCHEMBL7830363 | 0.76 | MIF (0.32) | MIFLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946144-B2 | Phosphonated glycopeptide and lipoglycopeptide antibiotics and uses thereof for the prevention and treatment of bone and joint infections | THE MEDICINES COMPANY (US) | 2015-02-03 | — | — | US | disclosed |
| US-8901072-B2 | Glycopeptide and lipoglycopeptide antibiotics with improved solubility | THE MEDICINES COMPANY (US) | 2014-12-02 | — | — | US | disclosed |
| US-20120149632-A1 | GLYCOPEPTIDE AND LIPOGLYCOPEPTIDE ANTIBIOTICS WITH IMPROVED SOLUBILITY | THE MEDICINES COMPANY (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149632-A1 | GLYCOPEPTIDE AND LIPOGLYCOPEPTIDE ANTIBIOTICS WITH IMPROVED SOLUBILITY | NGLY1, LGALS3BP, GYPA | MIF 1609/4885LMNA 1400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.